Glioblastoma multiforme (GBM), the most aggressive tumor in the central nervous system, poses significant challenges for its treatment due to its invasiveness, genetic heterogeneity, and limited drug delivery across the blood-brain barrier (BBB). Nanotechnology has emerged as an innovative therapeutic approach to fight this devastating disease by enhancing drug bioavailability, facilitating drug delivery across the BBB, and targeting tumor cells, allowing for precise delivery while minimizing damage to healthy tissue. A previous research introduced cell-derived magnetic nanovectors (CDMNVs), which consist of a lipid core encapsulating iron oxide nanoparticles and the drug regorafenib, coated with cell membranes extracted from patient-derived GBM cell cultures to provide an effective targeting of GBM cells in vitro exploiting homotypic affinity, a phenomenon where cancer cells recognize each other via specific membrane proteins.